Pleural Epithelioid Mesothelioma
NCI Definition: Malignant mesothelioma that arises from the pleura and is characterized by the presence of cells with epithelioid morphology. The epithelioid cells usually have eosinophilic cytoplasm, bland nuclei, and form tubulopapillary, microglandular, or sheet-like patterns. 
Pleural epithelioid mesotheliomas most frequently harbor alterations in BAP1, CDKN2A, NF2, CDKN2B, and SETD2 .
BAP1 Mutation, CDKN2A Loss, CDKN2B Loss, NF2 Mutation, and SETD2 Mutation are the most common alterations in pleural epithelioid mesothelioma .
There are 3 clinical trials for pleural epithelioid mesothelioma, of which 3 are open and 0 are completed or closed. Of the trials that contain pleural epithelioid mesothelioma as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open).
Mk-4830, celecoxib, and gemcitabine are the most common interventions in pleural epithelioid mesothelioma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.